Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma

George Van Buren, Ramesh K. Ramanathan, Alyssa M. Krasinskas, Ryan P. Smith, Gerard J. Abood, Nathan Bahary, Barry C. Lembersky, Yongli Shuai, Douglas M. Potter, David L. Bartlett, Amer H. Zureikat, Herbert J. Zeh, A. James Moser

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences